2+ release from the Golgi apparatus regulates key functions of the organelle, including vesicle trafficking. We found that the Golgi apparatus was the source of prolonged Ca 2+ release events that originated near the nuclei of primary cardiomyocytes. Golgi Ca 2+ release was unaffected by depletion of sarcoplasmic reticulum Ca
INTRODUCTION
The Golgi apparatus has an integral role in the modification, sorting, and packaging of macromolecules originating from the rough endoplasmic reticulum (ER), vesicular transport of secreted lipids, proteins, and carbohydrates, and the formation of lysosomes (1) . Ca 2+ within the Golgi apparatus regulates both its structure and function. For example, reduced Golgi Ca 2+ uptake has been associated with changes in structure, protein sorting, and vesicle trafficking (2, 3) . Localized increases in cytosolic Ca 2+ concentration due to Golgi Ca 2+ release have been suggested to control vesicle fusion and cargo transport (3) (4) (5) . This notion is supported by the identification of Ca 2+ -binding proteins associated with the Golgi membrane, which transduce local cytosolic Ca 2+ signals into regulatory events (6) . However, relatively little is known about the role of the Golgi apparatus as a Ca 2+ -signaling organelle or the pathways that regulate Golgi Ca 2+ release. The Ca 2+ concentration gradient across the Golgi apparatus membrane is generated by the secretory pathway Ca 2+ adenosine triphosphatase (ATPase) 1 (SPCA1) (2, 7, 8) and sarco/endoplasmic reticulum Ca 2+ -ATPase (SERCA) (9) (10) (11) . Ca 2+ -binding proteins within the Golgi lumen, such as calnuc, increase the Ca 2+ storage capacity of the organelle in a manner analogous to calsequestrin in the SR and ER (12) . Previous studies, most of which have been based on data from cell lines, have generally concluded that inositol 1,4,5-trisphosphate (IP 3 ) receptors (IP 3 Rs) mediate Golgi Ca 2+ efflux (3, (13) (14) (15) . However, in neonatal cardiomyocytes, Ca
2+
depletion of the trans-Golgi apparatus occurs in response to agonists of the ryanodine receptor (RyR), but not those of the IP 3 R (2) , suggesting that Ca 2+ regulation in the Golgi apparatus exhibits cell type specialization. The mechanism that mediates Ca 2+ efflux from Golgi apparatus has been studied indirectly by targeting Ca 2+ probes to the lumen of the organelle (8, 13, 14, 16) or by using selective disrupting agents to assess its contribution to cytosolic Ca 2+ transients (8, 17, 18) . However, it is possible that in cells that exhibit large ER and SR cytosolic Ca 2+ transients, Golgi Ca 2+ efflux may be obscured. Alternatively, because the Golgi apparatus encircles or is adjacent to the nucleus (2, 19) , the organelle might dictate local Ca 2+ signaling despite global cytosolic Ca 2+ transients. Released Ca 2+ may therefore have privileged access to both the Golgi apparatus microenvironment and the nucleoplasm.
We sought to identify Golgi Ca 2+ release events in cardiomyocytes, which exhibit large cytosolic ER-and SR-derived Ca 2+ transients, and to characterize the signaling pathways that control Ca 2+ release from the organelle. Our findings suggest that the Golgi apparatus is a nexus for b 1 -adrenergic signaling, which could dictate the local Ca 2+ concentration within the Golgi microenvironment, with consequent effects on protein trafficking in primary cardiomyocytes.
RESULTS

Prolonged Ca
2+ release events occur at the nuclear poles
To detect changes in local Ca 2+ release in the vicinity of the Golgi apparatus and associated nuclei, we obtained sequential x-y images from Fluo-4-loaded adult rat ventricular myocytes (ARVMs) with the confocal plane adjusted such that at least one of the two nuclei was in focus (Fig. 1A) . Nuclei in cardiomyocytes have an elongated morphology, and a localized 1 School of Biomedical Sciences, University of Leeds, Leeds LS29JT, UK. 2 
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Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS29JT, UK. 3 School of Molecular and Cellular Biology, University of Leeds, Leeds LS29JT, UK. *Corresponding author. E-mail: d.steele@leeds.ac.uk Ca 2+ release event was apparent at the lower "pole" of a nucleus. Subsequent frames (Fig. 1A , upper right) and corresponding surface plots (Fig.  1A , lower right) revealed a prolonged increase in nucleoplasmic Ca 2+ concentration. In line-scan images, localized Ca 2+ release events arising at the nuclear poles were of similar amplitude to Ca 2+ sparks but often exhibited a plateau phase of variable duration ( fig. S1 ).
The Golgi apparatus appeared as a series of flattened membranous sacs in electron micrographs and was consistently present at the nuclear poles in ARVMs, as indicated by diaminobenzidine (DAB) staining of the Golgi matrix protein GM130 ( fig. S2A ). The cis face of the Golgi apparatus was closely apposed to the nuclear envelope, and the trans face was bounded by mitochondria. Confocal microscopy of cardiomyocytes expressing green fluorescent protein (GFP) fused to a Golgi localization sequence identified the organelle at the nuclear poles and also Golgi transfer vesicles within the cytosol ( fig. S2B, left) . Preexposure of GFP-expressing cells to the selective Golgi-disrupting agent ilimaquinone (IQ) (20) resulted in complete loss of both the Golgi apparatus at the nuclear poles and the transfer vesicles ( fig.  S2B, right) . Because the Golgi apparatus was consistently located at the nuclear poles in ARVMs, we sought to establish whether the prolonged Ca 2+ release events colocalized with this organelle. We loaded ARVMs with Golgi-ID Green to identify the Golgi apparatus and Fluo-4 to detect changes in the cytosolic Ca 2+ concentration. An initial x-y confocal image revealed both the location of the Golgi apparatus and the evenly distributed cytosolic Fluo-4 signal (Fig. 1B, left) . The x-y image was then used to position the scan line through the Golgi apparatus at both ends of the nucleus and several bright cytosolic vesicles (Fig. 1B , left, broken line). On initiation of the line scan, the Golgi apparatus was initially highlighted as a series of bright horizontal lines corresponding to the Golgi-ID Green signal (Fig. 1B, middle) . However, because Golgi-ID Green bleaches rapidly ( fig. S3 ), cytosolic Fluo-4 fluorescence was the remaining stable component of the signal (Fig. 1B, right) . The prolonged Ca 2+ release events at the nuclear poles consistently aligned with the Golgi-ID signal but not typically with cytosolic vesicles.
Prolonged Ca
2+ release events are abolished by selective Golgi disruption
To further determine whether the Golgi apparatus was the source of the prolonged Ca 2+ release events, we performed confocal imaging in Fluo-4-loaded ARVMs exposed to IQ to disrupt the Golgi apparatus, with the scan line positioned longitudinally through the poles of at least one nucleus. In cells initially exhibiting repetitive Ca 2+ release events ( Fig. 2A) , exposure to IQ abolished Ca 2+ release. In contrast, IQ did not alter Ca 2+ events originating from the SR, as indicated by a lack of effect on the amplitude of the caffeine-induced Ca 2+ transient (Fig. 2B) , the frequency or amplitude of spontaneous SR Ca 2+ waves (Fig. 2C ), or the properties of localized SR Ca 2+ sparks (Fig. 2D ). Both the location of the prolonged Ca 2+ release events and their selective abolition with IQ suggested that the site of origin was the Golgi apparatus. Therefore, prolonged Ca 2+ release events arising at the nuclear poles will now be referred to as Golgi Ca 2+ release.
Golgi Ca 2+ release arises from a Ca 2+ pool that is distinct from the SR To characterize the properties of Golgi Ca 2+ release and its relationship to Ca 2+ release from the SR, we line-scan-imaged ARVMs that had been permeabilized to allow adjustment of cytosolic conditions, such that regular spontaneous SR Ca 2+ waves could be induced, with the scan line positioned longitudinally through both nuclei (Fig. 2E) . We assumed that increases in Ca 2+ that occurred near the nuclear poles were Golgi Ca 2+ release events. The image shows a Golgi Ca 2+ release event that originated close to one end of the lower nucleus. In this example, an SR Ca 2+ wave arose spontaneously in the middle of the cell during the Golgi Ca 2+ release event (Fig. 2E, arrow) , before propagating in both directions to the ends of the cardiomyocyte. The SR Ca 2+ wave did not affect the underlying time course of the Golgi Ca 2+ release ( Fig. 2G and fig. S4 ), suggesting that the Ca 2+ stores in the SR and Golgi are not interconnected. As shown in Fig. 1B , Ca 2+ released from the Golgi diffused further into the nucleoplasm than the cytosol (Fig. 2H ). This finding might be explained by the close proximity of the trans-Golgi apparatus to mitochondria ( fig. S2A ), which acts as a Ca 2+ sink (21) . Inhibition of mitochondrial Ca 2+ uptake with RU360 stimulated Golgi Ca 2+ uptake ( fig. S5 ), which was likely due to loss of Ca 2+ from the mitochondria that was consequently taken up by the Golgi. In another example, a spontaneous SR Ca 2+ wave arose close to the center of a permeabilized ARVM and then propagated in both directions to the ends of the cell (Fig. 2I, arrow) . The SR Ca 2+ wave triggered a prolonged Golgi Ca 2+ release originating at the pole of one nucleus. As shown in previous figures, this event exhibited a plateau phase, and both cytosolic and nucleoplasmic Ca 2+ concentrations increased (Fig. 2J ). Intact cardiomyocytes showed a similar interplay between SR Ca 2+ release and Golgi Ca 2+ release. In the example, Golgi Ca 2+ release originated close to one end of the lower nucleus and then the cell was field-stimulated during the plateau phase (Fig. 2, K and L) . The line profile showed that this form of global SR Ca 2+ release also had no detectable influence on the amplitude or time course of Golgi Ca 2+ release (Fig. 2M) . However, the global 
Golgi apparatus Ca 2+ release involves RyRs
We used various interventions to investigate the mechanisms underlying Ca 2+ uptake and release from the Golgi apparatus (Table 1 ). In permeabilized ARVMs perfused with a mock intracellular solution containing 120 nM free Ca 2+ , 17.6% of the cells exhibited Golgi Ca 2+ release, a percentage that was reduced by decreasing the free Ca 2+ concentration and that was enhanced by increasing this concentration. In intact ARVMs, Golgi Ca 2+ release was abolished by preincubation with ryanodine at a concentration that blocks RyR2 in its closed state or with the SERCA inhibitor thapsigargin. These findings suggest that RyR Ca 2+ efflux and SERCAmediated Ca 2+ uptake have a major role in Golgi Ca 2+ regulation in ARVMs. IP 3 can induce depletion of Golgi apparatus luminal Ca 2+ in various cell types (3, (13) (14) (15) . In addition, ET-1, which increases the IP 3 concentration, or IP 3 R agonists can induce Ca 2+ efflux from the closely apposed nuclear envelope (22) in mouse cardiomyocytes (21) . However, we found that ET-1 did not stimulate Golgi Ca 2+ release in intact ARVMs and that the IP 3 R blocker 2-APB did not affect the percentage of cells exhibiting Golgi Ca 2+ release under basal conditions. Similarly, in permeabilized cardiomyocytes, the IP 3 R agonist adenophostin A did not stimulate Ca 2+ release at the nuclear poles.
The b 1 -adrenergic pathway promotes Golgi Ca 2+ release b 1 -Adrenergic signaling affects SR Ca 2+ regulation by increasing cyclic adenosine monophosphate (cAMP) concentrations and activating both PKA (protein kinase A) and Epac pathways (23, 24) . Golgi Ca 2+ release from 11.4% of intact ARVMs under control conditions increased to 13, 23.3, and 26.3% in the presence of 20, 100, and 1000 nM isoproterenol, respectively (Fig. 3A) . This relatively small effect of isoproterenol on Golgi Ca 2+ release might be explained if the cAMP concentration was low in the vicinity of the Golgi apparatus-for example, due to local phosphodiesterase (PDE) activity. Consistent with this idea, in the presence of 10 nM isoproterenol, a concentration that did not trigger Golgi Ca 2+ release, the nonspecific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) increased the percentage of cells exhibiting Golgi Ca 2+ release to 55% (Fig. 3A) . However, in the presence of 5 or 10 nM isoproterenol, PDE3 inhibition with milrinone or PDE4 inhibition with rolipram, but not PDE2 inhibition with erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA), significantly increased the percentage of cells exhibiting Golgi Ca 2+ release to between 72.7 and 100% (Fig. 3A) . Inhibition of PDE3 or PDE4 typically induced repetitive Golgi Ca 2+ release, such that the frequency of Golgi Ca 2+ release was >10-fold greater relative to isoproterenol alone (Fig. 3 , B and C). PDE3 or PDE4 inhibition also increased Golgi Ca 2+ release amplitude relative to isoproterenol alone (Fig. 3D) .
The influence of isoproterenol and PDE inhibition on Ca 2+ regulation by the SR was also studied. In the absence of isoproterenol, milrinone but not rolipram increased spark frequency (Fig. 3E) . The addition of isoproterenol with rolipram or milrinone increased spark frequency by >200% (Fig. 3E) . Ca 2+ spark amplitude was significantly increased by isoproterenol in the absence and presence of rolipram, but not by rolipram by itself or milrinone, either by itself or with isoproterenol (Fig. 3F) . Spark duration was significantly decreased only with isoproterenol alone (Fig. 3G) . SR Ca 2+ content was significantly increased by application of isoproterenol alone, but not when combined with PDE3 or PDE4 inhibition (Fig. 3H) , consistent with an increased Ca 2+ leak from the SR under PDE3 or PDE4 inhibition.
Both Epac and PKA activation are required for b 1 -adrenergic stimulation of Golgi Ca 2+ release
The isoproterenol-induced SR Ca 2+ leak is partly due to activation of the Epac pathway and subsequent modification of RyR function by Ca 2+ / calmodulin-dependent protein kinase II (CaMKII) (23) . Therefore, the increase in the RyR2-mediated Ca 2+ leak triggered by inhibition of PDE3 (Fig. 3H ) could be explained if a local increase in cAMP concentration increases Epac activation. In ARVMs, the selective Epac activator 8-CPT did not increase the proportion of cells exhibiting Golgi Ca 2+ release above baseline unless combined with 2 nM isoproterenol (Fig. 3I) , a concentration that was used to minimize PKA activation. This effect of 8-CPT was blocked by the CaMKII inhibitor KN93 or by the phospholipase C (PLC) inhibitor U73122 (Fig. 3I ). Relative to 8-CPT or isoproterenol alone, the combination of 8-CPT and isoproterenol increased Golgi Ca 2+ release frequency about threefold (Fig. 3, J and K) . However, relative to 8-CPT alone, isoproterenol significantly increased Golgi Ca 2+ release amplitude, an effect that was further increased in the presence of 8-CPT and isoproterenol (Fig.  3L ) and was consistent with facilitation of Golgi Ca 2+ uptake. In contrast to the lack of effect on Golgi Ca 2+ release, 8-CPT alone increased Ca 2+ spark frequency to 210.2 ± 25.4 of the control value (Fig. 3M) . Isoproterenol also increased spark frequency to a similar extent, but the combined addition of 8-CPT and isoproterenol did not further increase spark frequency. SR Ca 2+ spark amplitude was significantly decreased by 8-CPT and significantly increased by isoproterenol (Fig. 3N ). 8-CPT and isoproterenol in combination increased Ca 2+ spark amplitude to a greater extent than did isoproterenol alone. SR Ca 2+ duration spark was shortened by isoproterenol but not by 8-CPT alone or isoproterenol and 8-CPT in combination (Fig. 3O) . As previously described (23), the differing effects of 8-CPT and isoproterenol on SR Ca 2+ spark properties likely reflect changes in SR Ca 2+ content because SR Ca 2+ content was significantly reduced by 8-CPT and significantly increased by isoproterenol (Fig. 3P) . However, when isoproterenol Table 1 . Modulation of Golgi Ca 2+ release in permeabilized and intact ARVMs. Confocal line-scan imaging was used to assess the effect of various interventions on Golgi Ca 2+ release in permeabilized or intact ARVMs. In permeabilized cells, lowering the Ca 2+ concentration from the control concentration of 120 to 70 nM significantly reduced, whereas raising to 250 nM significantly increased, the percentage of cells exhibiting Golgi Ca 2+ release (n = 31). Adenophostin A had no significant effect on Golgi Ca 2+ release. In intact ARVMs, Golgi Ca 2+ release was not observed after treatment with ryanodine or thapsigargin. Neither endothelin-1 (ET-1) nor 2-aminoethoxydiphenyl borate (2-APB) had a significant effect on Golgi Ca 2+ release. Data were obtained from three to six hearts per intervention.
Permeabilized ARVMs
Intact ARVMs rapid application of caffeine (n = 10 to 11 ARVMs). In (A) to (H), data were obtained from three to five hearts per protocol. In (I) to (P), data were obtained from three to four hearts per protocol. *P < 0.05, **P < 0.01, ***P < 0.005.
was added with 8-CPT, the SR Ca 2+ content was greater than control. The effects of 8-CPT on Ca 2+ sparks and the SR content are consistent with previous reports (25) . If the Golgi apparatus and the SR are similarly affected by 8-CPT and isoproterenol, the combined effect of Epac acting on the RyR and a sustained increase in Golgi Ca 2+ content could be necessary for stimulation of Golgi Ca 2+ release (Fig. 3I) . Consistent with this possibility, 6-benzoyladenosine (6-Bnz)-cAMP, which activates PKA but not Epac (26) , increased SR Ca 2+ spark frequency ( fig. S6, A and B) and Ca 2+ content in the SR ( fig. S6C ) but not Golgi Ca 2+ release ( fig. S6D ). b 1 -Adrenergic stimulation has been suggested to cause an increase in the concentration of nitric oxide (NO), which activates an RyR2-mediated Ca 2+ leak (27) . However, measurements of NO with diaminofluorescein-2 (DAF-2) showed that NO concentrations in ARVMs increased after exposure to the NO donor GSNO (S-nitroso-glutathione) but not to a supramaximal dose of isoproterenol ( fig. S7, A and B) . The NO synthase inhibitor L-NAME (L-nitroarginine methyl ester) failed to block the stimulating effect of isoproterenol on Golgi Ca 2+ release or SR Ca 2+ spark parameters ( fig. S7, C to G) . These data suggest that NO does not have a major role in the stimulating effect of b 1 -adrenoceptor activation on Ca 2+ sparks or Golgi Ca 2+ release in ARVMs.
Heart failure is associated with enhanced b 1 -adrenergic stimulation of Golgi Ca 2+ release
The abundance of PDE3 and PDE4 is decreased in hypertrophy and heart failure, which might therefore enhance the b 1 -adrenergic-mediated stimulation of Golgi Ca 2+ release (28) . Thus, we investigated the response to b 1 -adrenoceptor stimulation in the monocrotaline (MCT) model of right heart failure (29) . Right heart failure was associated with reductions in the abundance of PDE3A, PDE4A, PDE4B, and PDE4D (Fig. 4A) . Isoproterenol increased spark frequency (Fig. 4B ), spark amplitude (Fig. 4C) , and twitch amplitude (Fig. 4D) in ARVMs from control rats. In contrast, in ARVMs from rats with heart failure, isoproterenol (at 20 nM) caused only a small increase in SR Ca 2+ spark frequency without changing spark amplitude or the amplitude of the electrically stimulated Ca 2+ transient. The less pronounced effect of isoproterenol in cells from MCT-induced heart failure animals is consistent with the previously reported blunting of the b 1 -adrenergic response in this model (30) . However, unlike the effects on SR Ca 2+ regulation, isoproterenol markedly increased the percentage of heart failure cells exhibiting Golgi Ca 2+ release. This finding suggests that despite blunting of the b 1 -adrenergic response, decreased abundance of PDE3 and PDE4 facilitates the action of cAMP on the Golgi, as acute PDE inhibition does in normal cardiomyocytes.
Conditions that promote Golgi Ca
2+ release facilitate trafficking of VEGFR-1 to the surface membrane The Golgi apparatus is involved in the trafficking of proteins to the surface membrane (1) . Under control conditions, vascular endothelial growth factor receptor-1 (VEGFR-1) distribution was punctate and intracellular (Fig. 5A) , and VEGFR-1 colocalized with the Golgi apparatus resident protein GM130 (Fig. 5B) . Some cells also exhibited a striated VEGFR-1 pattern, which overlapped with the distribution of Nav1.1 (31), which is located within the sarcolemma/T tubules in cardiac cells (Fig. 5C ). However, only 29.1 ± 9.3% of control cells showed a striated or partially striated VEGFR-1 pattern, suggesting that the receptor is primarily localized within the Golgi apparatus and within cytosolic vesicles under control conditions. Incubation of ARVMs with isoproterenol, which had no effect on Golgi Ca 2+ release, did not affect the cellular distribution of VEGFR-1 (Fig. 5, A  and D) . However, all conditions that stimulated Golgi Ca 2+ release (Fig. 3 ) markedly increased the percentage of cells with a striated VEGFR-1 distribution (Fig. 5, A and D) , including exposure to 8-CPT in combination with isoproterenol. This increase in the percentage of cells with VEGFR-1 in a striated distribution was also present if the cells were subjected to field stimulation throughout the protocol (Fig. 5D) . Preincubation of cells with 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid-acetoxymethyl (BAPTA-AM) to buffer cytosolic Ca 2+ blocked the increase in the percentage of cells with a striated VEGFR-1 distribution (Fig. 5D ). These data suggest that stimulation of Ca 2+ cycling in the Golgi apparatus could facilitate trafficking of VEGFR-1 from the Golgi apparatus to the sarcolemma in ARVMs. However, with this experimental approach, it is not possible to establish with certainty whether VEGFR-1 receptors are functional and incorporated within the sarcolemmal membrane.
DISCUSSION
One potential limitation of the methodology used in the present study is that cytosolic Ca 2+ signals can originate from a number of different sources, which complicates the identification of Golgi Ca 2+ release. Nonetheless, we showed that prolonged Ca 2+ release events arise at the nuclear poles in ARVMs and colocalize with the Golgi apparatus (Fig. 1B) , and IQinduced disruption of the Golgi apparatus at the nuclear poles ( Fig. 2A) abolished Golgi Ca 2+ release, without affecting SR Ca 2+ regulation (Fig.  2, C and D) . These findings suggest that the prolonged Ca 2+ release events at the nuclear poles are the cytosolic consequence of Golgi apparatus Ca 2+ depletion described in various other cell types (8, 13, 14, 16) . The greater diffusion of Ca 2+ into the nucleus rather than the cytosol (Fig. 2E) is consistent with the close proximity of the trans-Golgi apparatus to mitochondria, which acts as a Ca 2+ sink (32) , and also the absence of active Ca 2+ uptake mechanisms within the nucleoplasm. Proximity to mitochondria might also explain why the Golgi apparatus at the nuclear poles is more likely to exhibit Ca 2+ release than cytosolic vesicles, for example, if mitochondrial Ca 2+ fluxes influence Golgi Ca 2+ regulation (32) .
Golgi Ca 2+ release involves RyR-mediated Ca 2+ efflux and SERCA Ca 2+ uptake
In ARVMs, Golgi Ca 2+ release was abolished by ryanodine, which is consistent with findings in HL-1 cells (which partially retain an adult cardiac phenotype) that functional RyRs are present within the Golgi (33) . In addition, caffeine-sensitive Ca 2+ efflux from both the trans and medial Golgi apparatus occurs in neonatal cardiac and HL-1 cells, respectively (2, 34) . These data suggest that in ARVMs, RyRs are an important component of the Golgi Ca 2+ efflux pathway. Basal Golgi Ca 2+ release could therefore be the equivalent of spontaneous Ca 2+ sparks. The luminal Golgi environment in particular differs from that of the SR in that it has calnuc as the major Ca 2+ buffer (9), which, unlike calsequestrin, does not affect RyR gating. The Ca 2+ -binding protein calumenin, which is also present within the Golgi apparatus, inhibits the direct activating effect of luminal Ca 2+ on RyR2 (35) . Interventions that modify the relationship spark frequency (23) . As with Ca 2+ sparks (37), PLC inhibition prevented stimulation of Golgi Ca 2+ release by isoproterenol + 8-CPT (Fig. 3I) . Therefore, IP 3 R activation may either directly (through Ca 2+ release) or indirectly (through CaMKII) facilitate Golgi Ca 2+ release when Epac is activated. In contrast to neonatal cardiomyocytes where Ca 2+ uptake into the transGolgi depends exclusively on SPCA1 (2), Golgi Ca 2+ release was abolished by thapsigargin, implicating SERCA as an important Ca 2+ uptake mechanism underlying this form of Ca 2+ release in ARVMs. However, this finding does not exclude the possibility that SPCA1 also contributes to Ca 2+ uptake in ARVMs.
Coincident Golgi apparatus and SR Ca 2+ release are functionally independent Once initiated, spontaneous or triggered global SR Ca 2+ release did not affect the underlying time course of Golgi Ca 2+ release (Fig. 2 , E to M). Because spontaneous SR Ca 2+ waves deplete the SR by 80 to 90% (38) , it is unlikely that Golgi Ca 2+ release and Ca 2+ sparks originate from a common Ca 2+ pool. Furthermore, in cardiomyocytes, the lumen of the nuclear envelope is contiguous with that of the SR, allowing Ca 2+ to diffuse freely between both compartments, and global SR Ca 2+ release is associated with rapid (peak,~170 ms) depletion of Ca 2+ in the lumen of nuclear envelope (39) . Therefore, the absence of an effect of global SR Ca 2+ release on the underlying time course of Golgi Ca 2+ release (Fig. 2 , E and K) excludes the nuclear envelope as a likely source of Ca 2+ and is consistent with anatomical and functional separation of the SR and Golgi Ca 2+ stores. Global SR Ca 2+ release did occasionally trigger prolonged Golgi Ca 2+ release (for example, Fig. 2, I and K). However, this finding could be explained by the presence of RyR2 within the Golgi apparatus (2), which would be expected to exhibit Ca 2+ -induced Ca 2+ release.
Golgi Ca 2+ release is stimulated by activation of the b 1 -adrenergic signaling pathway
We found that isoproterenol with PDE3 or PDE4 inhibition stimulated Golgi Ca 2+ release to a greater extent than did isoproterenol alone. This finding is consistent with compartmentalization of b 1 -adrenergic signaling (40) , such that the cAMP concentration at the Golgi membrane is affected by PDE3 and PDE4 activity. In support of this notion, multiple components of the b 1 -adrenergic signaling pathway are associated with scaffolding proteins, which are targeted to specific subcellular locations ( fig. S8 ). For example, muscle-specific A-kinase anchoring proteins (mAKAPs) form signaling complexes comprising PKA, Epac, PDE4D3, and protein phosphatase 2A (41) . mAKAPs are targeted to the nuclear envelope but are also associated with RyRs in cardiomyocytes (42, 43) . In addition, the scaffold protein myomegalin anchors PDE4D3 to the Golgi apparatus (44) , and particulate PDE3 is membrane-bound and also present in the perinuclear region (45) .
Golgi Ca 2+ regulation affects VEGFR-1 trafficking
Both the Ca 2+ within the Golgi apparatus and local cytosolic Ca 2+ regulate both the structure of the organelle and vesicle trafficking (2, 3, 6) . The effects of local cytosolic Ca 2+ may involve Golgi-associated calmodulinlike Ca 2+ -binding proteins (for example, calneuron1/2 and NCS-1), which regulate the activity of phosphatidylinositol 4-OH kinase IIIb, local synthesis of phospholipids, and vesicle trafficking (6) . b 1 -Adrenergic signaling also affects the function of the Golgi apparatus in various cell types (46, 47) .
Our findings provide a possible link between these two sets of observations. Because b 1 -adrenergic stimulation can facilitate Golgi Ca 2+ release (Fig. 3) , the influence of b 1 -adrenergic stimulation on the Golgi apparatus may involve Ca 2+ -dependent regulation. This possibility is supported by the effects on VEGFR-1 localization (Fig. 5 ). As has been described in endothelial cells (48) , VEGFR-1 was located primarily within the Golgi apparatus in ARVMs under control conditions (Fig. 5B) . However, all interventions that facilitated Golgi Ca 2+ release increased trafficking of VEGFR-1 to the surface membrane (Fig. 5, A and D) . This is of relevance to work showing that VEGFR-1 is involved in preconditioning, whereby brief periods of intermittent ischemia improve the functional and structural integrity of the heart after subsequent ischemia/reperfusion (49) . Overall PDE activity is inhibited during ischemic preconditioning (50) , and transient pharmacological PDE3 inhibition can mimic ischemic preconditioning (51) . The present work suggests that increased sarcolemmal abundance of VEGFR-1, secondary to b 1 -adrenoceptor-mediated effects on Golgi Ca 2+ , may contribute to these effects. Moreover, our findings suggest that activation of Epac may provide a way to increase sarcolemmal VEGFR-1, thereby facilitating the preconditioning response.
The current findings may also be relevant to work implicating local, rather than global, Ca 2+ regulation in the control of key cardiac signaling pathways (52) . b 1 -Adrenoceptor stimulation induces hypertrophy by a pathway that involves activation of Epac and subsequent effects that involve nuclear factor of activated T cells (NFAT) and/or myocyte enhancer factor 2 (MEF2) transcription factors ( fig. S5) (37, 53) . Both of these pathways are Ca 2+ -regulated. NFAT activation is controlled by the Ca 2+ / calmodulin-dependent phosphatase calcineurin, which is present at the nuclear poles (54) . Epac-induced activation of IP 3 receptors and consequent effects on nucleoplasmic Ca 2+ concentrations and CaMKII are required for the nuclear export of histone deacetylase 5 from the nucleus, which is necessary for MEF2 activation (37) . Local Golgi Ca 2+ release may influence these signaling pathways, particularly during the development of hypertrophy and heart failure, when sustained b 1 -adrenergic activation occurs, and the abundance of PDE3s and PDE4s is decreased (28) .
These data suggest that the Golgi apparatus is a juxtanuclear focal point for b 1 -adrenergic signaling in the myocardium, exhibits functional plasticity under pathological conditions, and can impose local changes in Ca 2+ concentration, despite the presence of global cytosolic Ca 2+ transients that are critical for the contractile function of cardiomyocytes. Furthermore, we showed that activation of the b 1 -adrenergic pathway has distinct effects on Ca 2+ release from the Golgi apparatus, which involve local regulation of cAMP concentrations by PDE3 and PDE4, and activation of Epac and PKA, with consequent effects on the trafficking of a receptor.
MATERIALS AND METHODS
Preparation of cells and solutions
Wistar rats (150 to 200 g) were sacrificed in accordance with the UK Home Office Guidance on the Operation of Animals (Scientific Procedures) Act of 1986. ARVMs were isolated by collagenase digestion as described previously (55) . Intact cardiomyocytes were superfused with solutions containing 113 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 1.0 mM CaCl 2 , 0.37 mM Na 2 HPO 4 , 5.5 mM glucose, and 5 mM Hepes (pH 7.1). Changes in cytosolic Ca 2+ concentration were detected by loading the cardiomyocytes with Fluo-4 AM (5 mM) for 15 min at room temperature (20°to 22°C). In some experiments, cells were permeabilized by exposure to saponin (10 mg/ml) in a mock intracellular solution for 10 min, before centrifugation and resuspension. The intracellular solution contained 100 mM KCl, 25 mM Hepes, 0.36 or 0.05 mM EGTA, 10 mM phosphocreatine, 5 mM adenosine triphosphate, and 5 mM Fluo-4 (pH 7.0). The free Ca 2+ and Mg 2+ concentrations were adjusted to 120 and 1 mM, respectively, by addition of CaCl 2 and MgCl 2 . Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich. Isoproterenol was obtained from Martindale Pharmaceuticals. In some experiments, the b 2 -antagonist ICI 118,551 (100 nM) was included in the solutions, although it did not influence the results reported here. Rolipram (10 mM), milrinone (10 mM), and IBMX (10 mM) were added to inhibit PDEs. 8-CPT (10 mM) and 6-Bnz-cAMP (600 mM) were used to selectively activate Epac or PKA, respectively. Caffeine (20 mM) was rapidly applied to induce a maximal SR Ca 2+ release. A high concentration of ryanodine (100 mM) was used to block RyRs in the closed state. Thapsigargin (2.5 mM) was applied to selectively inhibit SERCA. ET-1 (100 mM) was applied to increase IP 3 in ARVMs. 2-APB (10 mM) was applied as a blocker of IP 3 Rs. Preincubation with IQ (25 mM) was used to completely disrupt the Golgi apparatus (1 hour) or to disrupt Golgi Ca 2+ release (15 min). KN93 (1 mM) was used to inhibit CaMKII. U7322 (5 mM) was applied to inhibit PLC. RU360 (5 mM) was used to inhibit mitochondrial Ca 2+ uptake.
MCT-induced heart failure model
Experiments were approved by the local ethical committee and the UK Home Office. Male Wistar rats (200 g) received a single intraperitoneal injection of MCT to induce right ventricular failure (60 mg/kg in saline) or were injected with an equivalent volume of saline as previously described. Animals were weighed weekly for 3 weeks after injection and then daily. Ethical approval required that animals were killed upon displaying clinical signs of right heart failure, for example, dyspnea, cold extremities, lethargy, or any weight loss on consecutive days.
Experimental chamber and Ca 2+ imaging
The experimental chamber was placed on the stage of a Nikon Diaphot Eclipse TE2000 inverted microscope, and the cells were viewed using a 60× water immersion lens (Plan Apo, 1.2 numerical aperture). In most experiments, cells were imaged in line-scan mode using a confocal laserscanning unit (MicroRadiance 2000, Bio-Rad) attached to the side port of the microscope. Experiments involving rapid x-y confocal Ca 2+ imaging used an Andor Revolution confocal unit fitted with a Yokogawa X1 spinning disc running at 30 to 60 frames per second. All dyes were excited at 488 nm, and emitted fluorescence was measured at >515 nm. Image processing and analysis were done using ImageJ (http://rsb.info.nih.gov/ij/) software with plug-ins that allow automatic detection of localized Ca 2+ release in line-scan (https:// sites.google.com/site/sparkmasterhome/) or x-y images (56) .
Identification of the Golgi apparatus using electron or confocal microscopy
For electron microscopy, the left ventricle from paraformaldehyde-treated rat heart was sectioned at 50 mm on a vibrating microtome and incubated in an antibody to the Golgi protein GM130 (mouse; 1:200; BD Biosciences). After washing, sections were incubated in biotinylated donkey anti-mouse 1:200 (Invitrogen) before extravidin peroxidase (1:1500; Sigma) and visualization with DAB.
For confocal microscopy (Zeiss LSM700) of fixed cells, myocytes were cultured overnight in the presence of the CellLight Golgi-GFP baculovirus (Invitrogen), which expresses a fusion construct of a Golgi apparatus marker (targeted to N-acetylgalactosaminyltransferase-2) and GFP. The culture medium comprised Medium 199 with Hepes and the following added ingredients: 5 mM creatine, 5 mM taurine, 2 mM Na-pyruvate, and 2 mM L-carnitine. The solution also contained primocin (2 ml/ml) and 0.1 mM insulin. Six-well plates were laminin-coated before addition of cardiomyocytes at~25,000 cells/ml. After culture, cells were fixed (Dulbecco's phosphate-buffered saline -4% paraformaldehyde for 20 min) and then permeabilized (0.05% Triton X-100) before 4′,6-diamidino-2-phenylindole staining to allow both the Golgi apparatus (excitation, 488 nm; emission, >515 nm) and the nucleus (excitation, 360 nm; emission, 460 nm) to be imaged.
In imaging experiments analyzing changes in VEGFR-1 abundance at the sarcolemmal membrane or with the Golgi apparatus, intact cells were exposed to various conditions before fixing. This included preincubation in BAPTA-AM (2.5 mM) for 15 min before introduction of isoproterenol (10 nM), isoproterenol + 8-CPT (10 mM), or isoproterenol + rolipram (10 mM).
In some experiments, the cells were electrically field-stimulated (0.5 Hz) before and during exposure to the drugs. Colocalization was established using Alexa Fluor 488-labeled mouse anti-GM130 (1:10; BD Biosciences), a Nav1.1 rabbit primary (1:25; Alomone Labs), followed by donkey antirabbit Alexa Fluor 555 (Invitrogen), and a VEGFR-1 antibody (1:25; BD Systems Ltd.), followed by donkey anti-goat Alexa Fluor 488 (1:500; Invitrogen). For visualization of the Golgi apparatus in living cells, cardiomyocytes were loaded for 15 min with Golgi-ID Green (0.5 nmol/ml; Enzo Life Sciences), a membrane-permeant Golgi apparatus marker (excitation, 488 nM; emission, >515 nm). The Golgi-ID Green signal bleached rapidly ( fig. S2 ). Consequently, coloading with Fluo-4 and Golgi-ID Green allowed the Golgi apparatus to be identified in x-y confocal images before bleaching of the dye, which left the stable Ca 2+ -sensitive Fluo-4 signal within the cytosol (Fig. 1B) .
Immunoblotting
The free right ventricular heart wall was dissected, minced, and then homogenized for 4 × 10 s in 2 ml of cooled (~10°C) Laemmli buffer without b-mercaptoethanol, 63.5 mM tris (pH 6.8), 10% glycerol, 2% SDS, protease (Roche Applied Science), and phosphatase (Thermo Scientific Pierce) inhibitor cocktails at maximum power using an Ultra-Turrax T8 hand-held homogenizer. After the final homogenization step, tubes were centrifuged (2000g for 10 min at 15°C) to sediment cell debris and unprocessed material. The supernatant was immediately stored at −20°C. Protein concentration was determined by bicinchoninic acid assay (Sigma-Aldrich). b-Mercaptoethanol [5% (v/v)] was added to all samples before SDSpolyacrylamide gel electrophoresis. Separated proteins were transferred from polyacrylamide gels to polyvinylidene difluoride membranes, after which a standard immunoblotting procedure was used. The PDE3A antibody was obtained from FabGennix Inc., and the PDE4A, PDE4B, and PDE4D antibodies were gifts from M. Houslay (University of Glasgow).
Statistics
Results are presented as means ± SEM. Statistical significance was assessed using a t test, c 2 test, or analysis of variance (ANOVA) as appropriate. Differences between means were considered significant at P < 0.05. Statistics and graph plotting were done using Origin software (MicroCal).
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/8/398/ra101/DC1 Fig. S1 . Ca 2+ sparks and prolonged juxtanuclear Ca 2+ release events are of similar amplitude. Fig. S2 . The Golgi apparatus is consistently located at the nuclear poles and can be disrupted by IQ. Fig. S3 . Golgi-ID Green fluorescence bleaches rapidly. Fig. S4 . Properties of simultaneous SR and Golgi Ca 2+ release events suggest that the stores are anatomically distinct. 
